The new selective estrogen receptor modulator MDL 103,323 increases bone mineral density and bone strength in adult ovariectomized rats

Osteoporosis International

Volumn 10, Issue 5, 1999, Pages 369-376

  Ammann, ^a   Bourrin, S ^a   Bonjour, J P ^a   Brunner, F ^a   Meyer, J M ^a   Rizzoli, R ^a  

^a NONE

Author keywords

Bisphosphonate; Bone mineral density; Bone strength; IGF I; Osteoporosis; Ovariectomy; SERM

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DEOXYPYRIDINOLINE; ESTROGEN RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; MDL 103 323; OSTEOCALCIN; PAMIDRONIC ACID; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ABSORPTIOMETRY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BONE REMODELING; BONE STRENGTH; CONTROLLED STUDY; DOSE RESPONSE; ESTROGEN ACTIVITY; FEMALE; FEMUR NECK; HORMONE DETERMINATION; LUMBAR SPINE; MORPHOMETRICS; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; TIBIA; TRABECULAR BONE; URINALYSIS; VERTEBRA BODY;

ANALYSIS OF VARIANCE; ANIMALS; BIOMECHANICS; BONE DISEASES, METABOLIC; BONE REMODELING; CLOMIPHENE; DIPHOSPHONATES; FEMALE; INSULIN-LIKE GROWTH FACTOR I; ORGAN SIZE; OVARIECTOMY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TIBIA; UTERUS;

EID: 0032700731     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980050242     Document Type: Article

References (42)

1. Christiansen C, Lindsay R. Estrogens, bone loss and preservation. Osteoporos Int 1991;1:7-13.
2. Ribot C, Tremollières F. Anti-oestrogens and bone. Ann Endocrinol 1995;56:603-8.
3. Kalu DN, Salerno E, Liu CC, Echon R, Ray M, Garzazapta M, et al. A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat. Bone Miner 1991;15:109-23.
4. Black LJ, Sato M, Rowley ER, et al. Raloxifene (Ly139481 HC) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63-9.
5. Evans G, Bryant HU, Magee D, Sato M, Turnes RT. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 1994;134:2283-8.
6. Goulding A, Gold E. In the ovariectomized rat, tamoxifen conserves bone similarly in parathyroid-intact and parathyroidectomized animals. Bone 1994;15:497-503.
7. Sato M, McClintock C, Kum J, et al. Dual-energy X-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J Bone Miner Res 1994;9:715-24.
8. Sato M, Kum J, Short LL, Slemenda CW, Bryant HU. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J Pharmacol Exp Ther 1995;272:1252-9.
9. Turner CH , Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 1994;135:2001-5.
10. Chen HK, Ke HZ, Jee WSS, Ma YF, Pirie CM, Simmons HA, et al. Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy X-ray absorptiometric and histomorphometric study. J Bone Miner Res 1995;10:1256-62.
11. Chen HK, Ze HZ, Lin CH, et al. Droloxifene inhibits cortical bone turnover associated with estrogen deficiency in rats. Bone 1995;17(Suppl4):S175-9.
12. Ke HZ, Che HK, Qi H, et al. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats. Bone 1995;17:491-6.
13. Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD. Droloxifene, a new estrogen antagonist agonist, prevents bone loss in ovariectomized rats. Endocrinology 1995;136:2435-41.
14. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY 129481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996;11:835-42.
15. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone 1996;18:621-7.
16. Delmas PD, Bjarnason NH, Mitlak HM, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7.
17. Fentiman IS, Saad Z, Caleffi M, Chaudary MA, Fogelman I. Tamoxifen protects against steroid-induced bone loss. Eur J Cancer 1992;28:684-5.
18. Friedl A, Jordan VC, Pollak M. Suppression of serum insulin-like growth factor-I levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 1993;29A:1368-72.
19. Ward RL, Morgan G, Dalley D, Kelly PJ. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 1993;22:87-94.
20. Love RR, Bardon HS, Mazess RB, Epstein S, Chappell RJ. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994;154:2585-8.
21. Grey AB, Stapleton JP, Evans MC, Tatnell MAA, Ames RW, Reid IR. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 1995;99:636-41.
22. Powles T, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84.
23. Ettinger B, Black D, Cummings S, Genant H, Glüer C, Lips P, et al. Raloxifene reduces the risk of incident vertebral fractures: 24-month interim analyses. Osteoporos Int 1998;8 (Suppl 3):11.
24. Ammann P, Rizzoli R, Caverzasio J, Müller K, Slosman D, Bonjour JP. IGF-I and pamidronate increase bone mineral density in ovariectomized adult rats. Am J Physiol 1993;265:770-6.
25. Ammann P, Rizzoli R, Caverzasio J, Shigematsu T, Slosman D, Bonjour JP. Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density. J Bone Miner Res 1993;8:1491-8.
26. Ammann P, Rizzoli R, Meyer JM, Bonjour JP. Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats. Osteoporos Int 1996;6:219-27.
27. Ammann P, Rizzoli R, Slosman D, Bonjour JP. Sequential and precise in vivo measurement of bone mineral density in rats using dual-energy X-ray absorptiometry. J Bone Miner Res 1992;7:311-6.
28. Maugars Y, Ammann P, Caverzasio J, Rizzoli R, Meyer JM, Bonjour JP. Aluminum sensitizes ovariectomized rats on fluoride therapy. Osteoporos Int 1996;6(Suppl 1):259.
29. Bourrin S, Palle S, Pupier R, Vico L, Alexandre C. Effects of physical training on bone adaptation in three zones of the rat tibia. J Bone Miner Res 1995;10:1745-52.
30. Parfitt AM. Bone histomorphometry: standardization of nomenclature, symbols and units. J Bone Miner Res 1987;2:595-610.
31. Parfitt AM. Stereologic basis of bone histomorphometry: theory of quantitative microscopy and reconstruction of the third dimension. In: Recker RR, editor. Bone histomorphometry: techniques and interpretation. Boca Raton, FL: CRC Press, 1983:53-89.
32. Ammann P, Rizzoli R, Bonjour JP. Preclinical evaluation of new therapeutic agents for osteoporosis. In: Meunier P, editor. Osteoporosis: diagnosis and management. London: Martin Dunitz, 1998:257-73.
33. Kalu DN. The ovariectomized rat model of postmenopausal bone loss. Bone Miner 1991;15:175-91.
34. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-80.
35. Meunier PJ, Boivin G. Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone 1997;21:373-7.
36. Jorgensen PH, Bak B, Andreassen TT. Mechanical properties and biochemical composition of rat cortical femur and tibia after long-term treatment with biosynthetic human growth hormone. Bone 1991;12:353-9.
37. Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. Bone 1993;14:595-608.
38. Ammann P, Rizzoli R, Caverzasio J, Bonjour JP. Fluoride potentiates the osteogenic effects of IGF-I in aged ovariectomized rats. Bone 1998; 22:39-43.
39. Mitlak HM, Burdette-Miller P, Schoenfeld D, Neer RM. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat. J Bone Miner Res 1996;11:430-9.
40. Bagi CM, Brommage R, Deleon L, Adams S, Rosen D, Sommer A. Benefit of systemically administered rhIGF-I, rhIGF-I/IGFBP-3 on cancellous bone in ovariectomized rats. J Bone Miner Res 1994;9:1301-12.
41. Huynh H, Tetenes E, Wallace L, Pollak M. In vivo inhibition of insulin-like growth factor-I gene expression by tamoxifen. Cancer Res 1993;53:2534-7.
42. Schürch MA, Rizzoli R, Slosman D, Vadas L, Vergnaud P, Bonjour JP. Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with a recent hip fracture. Ann Intern Med 1998;128:801-9.